Intellia Therapeutics (NTLA) Accumulated Depreciation & Amortization (2015 - 2025)
Intellia Therapeutics (NTLA) reported Accumulated Depreciation & Amortization of $58.6 million for Q4 2025, up 17.94% year-over-year from $49.7 million in Q4 2024, and up 17.94% on a QoQ basis from $49.7 million in Q4 2024.
Intellia Therapeutics (NTLA) has 11 years of Accumulated Depreciation & Amortization data on file, last reported at $58.6 million in Q4 2025.
- Quarterly Accumulated Depreciation & Amortization rose 17.94% year-over-year to $58.6 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $58.6 million (up 17.94% YoY) and the FY2025 annual result came in at $58.6 million, up 17.94% from the prior year.
- Accumulated Depreciation & Amortization grew to $58.6 million in Q4 2025 per NTLA's latest filing, from $49.7 million in the prior quarter.
- Across five years, Accumulated Depreciation & Amortization topped out at $58.6 million in Q4 2025 and bottomed at $26.1 million in Q4 2021.
- The 5-year median for Accumulated Depreciation & Amortization is $39.9 million (2023), against an average of $41.5 million.
- The widest annual swing landed in 2021, when Accumulated Depreciation & Amortization surged 35.09%; it then grew 17.94% in 2025.
- Tracing NTLA's Accumulated Depreciation & Amortization over 5 years: stood at $26.1 million in 2021, then rose by 27.13% to $33.2 million in 2022, then rose by 20.07% to $39.9 million in 2023, then rose by 24.66% to $49.7 million in 2024, then gained by 17.94% to $58.6 million in 2025.
- Per Business Quant, the three latest NTLA Accumulated Depreciation & Amortization figures stand at $58.6 million (Q4 2025), $49.7 million (Q4 2024), and $39.9 million (Q4 2023).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn |
| 10 | Intellia Therapeutics | 1.63 Bn | 1.63 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 58.61 Mn |
| Dec 31, 2025 | 58.61 Mn |
| Dec 31, 2024 | 49.69 Mn |
| Dec 31, 2024 | 49.69 Mn |
| Dec 31, 2023 | 39.86 Mn |
| Dec 31, 2023 | 39.86 Mn |
| Dec 31, 2022 | 33.20 Mn |
| Dec 31, 2022 | 33.20 Mn |
| Dec 31, 2021 | 26.11 Mn |
| Dec 31, 2021 | 26.11 Mn |
| Dec 31, 2020 | 19.33 Mn |
| Dec 31, 2020 | 19.33 Mn |
| Dec 31, 2019 | 13.87 Mn |
| Dec 31, 2019 | 13.87 Mn |
| Dec 31, 2018 | 8.61 Mn |
| Dec 31, 2018 | 8.61 Mn |
| Dec 31, 2017 | 4.33 Mn |
| Dec 31, 2017 | 4.33 Mn |
| Dec 31, 2016 | 1.43 Mn |
| Dec 31, 2016 | 1.43 Mn |
| Dec 31, 2015 | 331,000.00 |
| Dec 31, 2015 | 331,000.00 |